The KATHERINE trial studied the benefits of adjuvant ado-trastuzumab emtansine (T-DM1) over adjuvant trastuzumab only in HER2+ breast cancer patients who achieved pIR after neoadjuvant taxane with or without anthracycline and trastuzumab. The gene discussed is ERBB2; the disease is breast carcinoma.